Physician profile
Emily Sheldon
NPI 1598325631
$1,630.94
in general payments reported to CMS, 2019-2025
19 companies · $23.03 in 2025
The $23.03 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $478 · 2023: $482 · 2024: $441 · 2025: $23.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $488.35 | 2021-2024 | Briviact, Fintepla |
| Gilead Sciences, INC. | $199.16 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $125.78 | 2021-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $109.15 | 2024 | Wegovy |
| Pfizer INC. | $102.90 | 2022-2024 | |
| Intuitive Surgical, INC. | $91.76 | 2023 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.89 | 2022-2024 | Jardiance, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $76.23 | 2021-2022 | |
| Eisai INC. | $70.92 | 2024 | |
| Melinta Therapeutics, LLC | $64.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.46 | 2021-2023 | Dificid, Zerbaxa, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $30.28 | 2023 | Uptravi, Opsumit |
| La Jolla Pharmaceutical Company | $30.08 | 2023 | Xerava |
| Abbvie INC. | $23.34 | 2022 | |
| Scpharmaceuticals INC. | $23.03 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.75 | 2024 | |
| Phadia US INC. | $16.14 | 2021 | |
| Abiomed | $14.54 | 2023 | Impella |
| Alexion Pharmaceuticals, INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Sheldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.